...
首页> 外文期刊>Clinical and experimental pharmacology & physiology >Diabetes-induced changes in 5-hydroxytryptamine modulation of vagally-induced bradycardia in rat heart.
【24h】

Diabetes-induced changes in 5-hydroxytryptamine modulation of vagally-induced bradycardia in rat heart.

机译:糖尿病引起的大鼠心脏中阴道诱发的心动过缓的5-羟色胺调节作用变化。

获取原文
获取原文并翻译 | 示例

摘要

1. In the present study, we investigated how alloxan-induced diabetes affects the ability of 5-hydroxytryptamine (5-HT) to modulate bradycardia induced in vivo by electrical stimulation of the vagus nerve in pithed rats. We also analysed the type and/or subtype of 5-HT receptors involved. 2. Diabetes was induced in male Wistar rats with a single injection of alloxan (150 mg/kg, s.c.). Four weeks later, rats were anaesthetized, pretreated with atenolol and pithed. Electrical stimulation (3, 6 and 9 Hz) of the vagus nerve resulted in frequency dependent decreases in heart rate (HR). 3. In diabetic rats, intravenous bolus administration of high doses of 5-HT (100 and 200 microg/kg) increased the bradycardia induced by vagal electrical stimulation. Similarly, low doses (10 microg/kg) of the 5-HT(1/7) receptor agonist 5-carboxamidotryptamine (5-CT), increased vagally induced bradycardia. However, at high doses (50, 100 and 150 microg/kg), 5-CT reduced the bradycardia. Attenuation of the vagally induced bradycardia evoked by the higher doses of 5-CT was reproduced by L-694,247 (50 microg/kg), a selective agonist for the non-rodent 5-HT(1B) and 5-HT(1D) receptors. Enhancement of the vagally induced bradycardia elicited by low doses of 5-CT was reproduced by the selective 5-HT(1A) receptor agonist 8-hydroxydipropylaminotretalin hydrobromide (8-OH-DPAT; 50 microg/kg). These stimulatory and inhibitory actions on vagal stimulation-induced bradycardia in diabetic rats were also observed after administration of exogenous acetylcholine. 4. Vagally induced bradycardia in diabetic rats was not affected by administration of the selective 5-HT(2) receptor agonist alpha-methyl-5-HT (150 microg/kg), the selective 5-HT(3) receptor agonist 1-phenylbiguanide (150 microg/kg) or the selective 5-HT(1B) receptor agonist CGS-12066B (50 microg/kg). 5. Enhancement of the electrical stimulation-induced bradycardia in diabetic rats caused by 5-CT (10 microg/kg) or 8-OH-DPAT (50 microg/kg) was abolished by the selective 5-HT(2/7) receptor antagonist mesulergine (1 mg/kg) and the selective 5-HT(1A) receptor antagonist WAY-100,635 (100 microg/kg), respectively. Similarly, pretreatment with the non-selective 5-HT(1) receptor antagonist methiothepin (0.1 mg/kg) blocked the inhibitory effect of 5-CT (50 microg/kg) on the bradycardia induced by vagal electrical stimulation in diabetic rats. BRL-15572 (2 microg/kg), a selective 5-HT(1D) receptor antagonist, inhibited the action of L-694,247 (50 microg/kg), a selective agonist for the non-rodent 5-HT(1B) and 5-HT(1D) receptors, on the vagally induced bradycardia. 6. In conclusion, in the present study, experimental diabetes evoked changes in both the nature and 5-HT receptor types/subtypes involved in vagally induced bradycardia.
机译:1.在本研究中,我们研究了四氧嘧啶诱发的糖尿病如何影响5-羟色胺(5-HT)调节通过电刺激迷走神经的迷走神经在体内诱发的心动过缓的能力。我们还分析了所涉及的5-HT受体的类型和/或亚型。 2.一次注射四氧嘧啶(150 mg / kg,皮下注射)在雄性Wistar大鼠中诱发糖尿病。四周后,麻醉大鼠,用阿替洛尔预处理并脱髓鞘。迷走神经的电刺激(3、6和9 Hz)导致心率(HR)频率依赖性降低。 3.在糖尿病大鼠中,静脉推注大剂量5-HT(100和200 microg / kg)可增加迷走神经电刺激引起的心动过缓。同样,低剂量(10 microg / kg)的5-HT(1/7)受体激动剂5-羧酰胺基色胺(5-CT)增加了阴道诱发的心动过缓。但是,在高剂量(50、100和150 microg / kg)下,5-CT可以减少心动过缓。 L-694,247(50 microg / kg)对非啮齿类动物5-HT(1B)和5-HT(1D)受体具有选择性激动剂,可通过更高剂量的5-CT诱发阴道诱发的心动过缓。 。选择性5-HT(1A)受体激动剂8-羟基二丙基氨基海藻糖氢溴酸盐(8-OH-DPAT; 50 microg / kg)再现了低剂量5-CT引起的阴道诱发的心动过缓。给予外源性乙酰胆碱后,对糖尿病大鼠迷走神经刺激引起的心动过缓的这些刺激和抑制作用也被观察到。 4.糖尿病大鼠的阴道诱发性心动过缓不受选择性5-HT(2)受体激动剂α-甲基-5-HT(150 microg / kg),选择性5-HT(3)受体激动剂1-的影响苯基双胍(150微克/千克)或选择性5-HT(1B)受体激动剂CGS-12066B(50微克/千克)。 5.选择性5-HT(2/7)受体消除了5-CT(10 microg / kg)或8-OH-DPAT(50 microg / kg)引起的糖尿病大鼠电刺激引起的心动过缓的增强拮抗剂美舒乐金(1 mg / kg)和选择性5-HT(1A)受体拮抗剂WAY-100,635(100 microg / kg)。类似地,用非选择性5-HT(1)受体拮抗剂美沙西平(0.1 mg / kg)进行的预处理可阻断5-CT(50 microg / kg)对糖尿病大鼠迷走神经电刺激引起的心动过缓的抑制作用。 BRL-15572(2 microg / kg),一种选择性的5-HT(1D)受体拮抗剂,抑制L-694,247(50 microg / kg)的作用,L-694,247(50 microg / kg),一种非啮齿类动物5-HT(1B)和阴道诱发的心动过缓上的5-HT(1D)受体。 6.总之,在本研究中,实验性糖尿病诱发了由阴道引起的心动过缓所涉及的自然和5-HT受体类型/亚型的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号